Rezdiffra is an innovative, once-daily medication that targets key catalysts of NASH. Remarkably, it is the first approved treatment for NASH, marking a groundbreaking advancement in the field.

Resmetirom is the first FDA-approved drug for NASH with liver fibrosis, offering a new treatment option alongside lifestyle changes. Clinical trials demonstrated significant NASH resolution and ...

Rezdiffra, a once-daily oral medication targeting the liver, is the first of its kind approved by the FDA for NASH treatment. It is designed to address the core causes of NASH by acting as a ...

He believes that NASH treatment is destined to progress rapidly towards combination treatment, just as hep C has, and that these doctors “wrote the book” on how to combine two unapproved ...

Nonalcoholic steatohepatitis (NASH) is a type of nonalcoholic fatty ... Following your doctor’s recommended treatment is important for preventing complications from MASH. Consider asking your ...

To test their new drug, the researchers conducted experiments on mice that were fed a high-fat diet, which typically leads to obesity and liver disease. They gave some of the mice CTPI-2 as a ...